2022
Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.
Zengin Z, Meza L, Malhotra J, Salgia S, Ely J, Hsu J, Kelley E, Mead H, Dizman N, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies. Journal Of Clinical Oncology 2022, 40: 185-185. DOI: 10.1200/jco.2022.40.6_suppl.185.Peer-Reviewed Original ResearchCOVID-19 vaccinationBlood samplesSystemic treatmentAntibody titersGenitourinary malignanciesSubset of ptsImmune checkpoint inhibitorsBaseline blood samplesLong-term efficacyAdditional blood samplesCOVID-19 vaccineSARS-CoV-2Short-term effectivenessCancer ptsSerologic outcomeCheckpoint inhibitorsGenitourinary cancersMedian ageTherapy cyclesBladder cancerTCR sequencingIgG ELISACoV-2Host immunityVaccination
2021
Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data.
Zengin Z, Weipert C, Hsu J, Salgia N, Hensel C, Maughan B, Rathi N, Goel D, Agarwal N, Choueiri T, Pal S. Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. Journal Of Clinical Oncology 2021, 39: 347-347. DOI: 10.1200/jco.2021.39.6_suppl.347.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaGenomic profilingCtDNA alterationsMost common histologySubset of ptsRenal cell carcinomaSeparate validation cohortTissue-based assessmentProportion of alterationsCommon histologyMedian timeValidation cohortCell carcinomaCtDNA assessmentClear cellsCtDNA analysisTumor DNACohortGene panelTissue samplesTissue assessmentMonthsOnly alterationSignificant differencesPatients